Literature DB >> 10958836

Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice.

J M Lenhard1, D K Croom, J E Weiel, A Spaltenstein, D J Reynolds, E S Furfine.   

Abstract

Human immunodeficiency virus (HIV) protease inhibitors (PI) may alter lipid metabolism in patients with acquired immunodeficiency syndrome (AIDS). However, the influence of dietary fat on the metabolic effects of PI therapy remains unknown. AKR/J mice were fed high or low fat diets and treated with the PI indinavir (IDV), nelfinavir (NFV), saquinavir (SQV) or amprenavir (APV) by subcutaneous delivery for 2 wk. Serum concentrations of glucose, insulin, triglyceride, free fatty acid, glycerol, pancreatic lipase, bilirubin, alkaline phosphatase, blood urea nitrogen and PI, and interscapular and epididymal fat weights were determined. Some metabolic effects of PI were dependent on diet. IDV- and NFV-treated mice had greater serum glucose concentration and body weight; IDV-treated mice had lower serum insulin; NFV-treated mice had greater interscapular fat mass; and SQV treated mice had lower serum triglyceride concentration than control mice fed the low but not the high fat diet. In contrast, NFV- and IDV-treated mice had greater triglyceride concentration and blood urea nitrogen, and SQV treated mice had greater serum cholesterol than control mice fed the high but not the low fat diet. The serum concentration of SQV was lower in mice fed the high fat compared with the low fat diet. Other effects were not dependent on diet. IDV- and NFV-treated mice had greater fatty acids, and IDV-treated mice had greater pancreatic lipase, bilirubin and alkaline phosphatase than control mice fed either diet. APV treatment had little effect on these serum measurements. Thus, changes in dietary fat can influence some but not all of the effects of PI on metabolism. Furthermore, each PI produces different effects in vivo, indicating that various PI affect distinct metabolic pathways.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10958836     DOI: 10.1093/jn/130.9.2361

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  5 in total

1.  Critical role for the Ets transcription factor ELF-1 in the development of tumor angiogenesis.

Authors:  Xuling Huang; Courtney Brown; Weihua Ni; Elizabeth Maynard; Alan C Rigby; Peter Oettgen
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

2.  Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice.

Authors:  Paul J Pistell; Sunita Gupta; Alecia G Knight; Michelle Domingue; Romina M Uranga; Donald K Ingram; Indu Kheterpal; Carmen Ruiz; Jeffrey N Keller; Annadora J Bruce-Keller
Journal:  Antiviral Res       Date:  2010-10-21       Impact factor: 5.970

Review 3.  Amprenavir: a review of its clinical potential in patients with HIV infection.

Authors:  S Noble; K L Goa
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

4.  Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance.

Authors:  Sunita Gupta; Alecia G Knight; Boriss Y Losso; Donald K Ingram; Jeffrey N Keller; Annadora J Bruce-Keller
Journal:  Antiviral Res       Date:  2012-05-09       Impact factor: 5.970

5.  Lopinavir/Ritonavir Impairs Physical Strength in Association with Reduced Igf1 Expression in Skeletal Muscle of Older Mice.

Authors:  Siu Wong; Shalender Bhasin; Carlo Serra; Yanan Yu; Lynn Deng; Wen Guo
Journal:  J AIDS Clin Res       Date:  2013-06-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.